Urothelial Carcinoma
Urothelial Carcinoma
Zachary BessetteUrothelial Carcinoma | December 6, 2022
A new study sheds light on the natural history and outcomes of UCB with isolated lymph node metastasis after resection.
Read More
Zachary BessetteMuscle Invasive Urothelial Carcinoma | December 6, 2022
DLRS-based MLP was clinical useful in distinguishing non-muscle-invasive bladder cancer from muscle-invasive bladder cancer.
Emily MenendezUpper Tract Urothelial Carcinoma | November 30, 2022
A research team recently investigated the use of tubular damage biomarkers as prognostic markers for upper tract UC.
Leah LawrenceMuscle Invasive Urothelial Carcinoma | November 28, 2022
MRE11 “has been identified as a candidate predictive biomarker," as higher levels are associated with more ...
Daniel Tennenbaum, MDJournal | November 22, 2022
Up to one-third of all UTUC patients present with variant histology, such as squamous or micropapillary features.
Akhil Abraham Saji, MDJournal | November 22, 2022
1 of 4 will UTUC patients will have a variant histologic subtype such as squamous cell, micropapillary, or neuroendocrine.
David Ambinder, MDJournal | November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
David Ambinder, MDJournal | November 22, 2022
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
Leah LawrenceUpper Tract Urothelial Carcinoma | November 15, 2022
Out of 17 studies, adjuvant radiotherapy had no significant effect on UTUC, and radiotherapy had a negative impact on OS.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Shilpa Gupta, MD, discusses the impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
An extra 2 chemotherapy cycles in patients with advanced urothelial carcinoma didn't reduce tumor size in most cases.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Enfortumab vedotin led to longer OS than chemotherapy in previously treated urothelial carcinoma.
Cecilia BrownAdvanced Urothelial Carcinoma | November 10, 2022
Most patients with locally advanced or metastatic urothelial carcinoma did not receive first-line systemic therapy.
The UromigosUromigos Live and Unplugged | November 8, 2022
Petros Grivas, MD, PhD, Director of UW Medicine's GU Cancers Program, talks about the efficacy of sacituzumab govitecan.
The UromigosUromigos Live and Unplugged | November 8, 2022
Shilpa Gupta, MD discusses maintenance therapy for bladder cancer, including the current standard of care and ongoing trials.
The UromigosUromigos Live and Unplugged | November 8, 2022
Thomas Powles, MBBS, MRCP, MD gives an overview of highlights from The Uromigos: Live & Unplugged bladder cancer session.
The UromigosUromigos Live and Unplugged | November 8, 2022
Matthew Galsky, MD gives insight on adjuvant nivolumab trials, including use in unselected patients and overall survival.
The UromigosUromigos Live and Unplugged | November 8, 2022
Kala Sridhar talks about bladder-sparing treatments for urothelial carcinoma and how patient populations are shifting.
The UromigosUromigos Live and Unplugged | November 8, 2022
Jonathan Rosenberg, MD talks about the development of enfortumab vedotin, including monotherapy info and combination data.
Emily MenendezMuscle Invasive Urothelial Carcinoma | October 31, 2022
At a 36-month follow-up, the EFS and OS rates were 74.4% and 83.8% in the ITT group, and 92% of patients underwent RC.
Advertisement
Advertisement